InVivo Therapeutics Holdings Corp. (NVIV) today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules of 1,715,240 shares of its common stock at a purchase price of $1.75 per share. The Company also issued to the purchasers of such shares unregistered warrants to purchase up to 1,715,240 shares of common stock. The warrants have an exercise price of $1.62 per share, are exercisable immediately, and will expire five and one-half years from the date of issuance.

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs on Nov. 21.) ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ) Alnylam ...

InVivo Therapeutics Holdings Corp. (NVIV) today announced the pricing of a public offering of 2,545,455 shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof), together with warrants to purchase up to 2,545,455 shares of common stock at a combined effective price to the public of $2.75 per share (or pre-funded warrant) and associated warrant. The gross proceeds from this offering are expected to be approximately $7.0 million, before deducting the placement agent fees and estimated offering expenses payable by InVivo Therapeutics.

InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV) today announced the closing of its previously announced public offering of 2,545,455 shares of common stock (or pre-funded warrants to purchase common stock in lieu thereof), together with warrants to purchase up to 2,545,455 shares of common stock at a combined effective price to the public of $2.75 per share (or pre-funded warrant) and associated warrant. The gross proceeds from this offering were approximately $7.0 million, before deducting the placement agent fees and estimated offering expenses payable by InVivo Therapeutics.

InVivo Therapeutics Holdings Corp. (NVIV) today announced that it has entered into definitive agreements with several institutional investors for the purchase and sale of 1,715,240 shares of its common stock at a purchase price of $1.75 per share in a registered direct offering priced at-the-market under Nasdaq rules. The Company also agreed to issue to the investors unregistered warrants to purchase up to 1,715,240 shares of common stock. The warrants have an exercise price of $1.62 per share, are exercisable immediately, and will expire five and one-half years following the date of issuance. The closing of the offering is expected to occur on or about April 17, 2020, subject to the satisfaction of customary closing conditions.

The CEO of PixarBio Corp., a biopharma startup founded in Massachusetts, has been found guilty of defrauding hundreds of investors out of approximately $12.7 million.